Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITAL
2024-516386-36-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of capivasertib in B-cell non-Hodgkin lymphoma (B-NHL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and 1 more, sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Jul 2024; status: completed.
02
Drugs
capivasertib
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-516386-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516386-36-00.